Loading company…
MoonLake Immunotherapeutics develops Sonelokimab, a treatment candidate for inflammatory diseases.
Founded in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland, and develops treatments for inflammatory diseases. Its lead product, Sonelokimab, is being studied for hidradenitis suppurativa, psoriatic arthritis, psoriasis and ankylosing spondylitis. In June 2023, the company raised USD 400.00 mn in a private placement.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in